Xenetic Biosciences, Inc. (NASDAQ:XBIO – Get Free Report) saw a large growth in short interest in June. As of June 30th, there was short interest totaling 23,589 shares, a growth of 158.0% from the June 15th total of 9,143 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average daily volume of 19,757 shares, the short-interest ratio is currently 1.2 days.
Institutional Trading of Xenetic Biosciences
A hedge fund recently raised its position in Xenetic Biosciences stock. Renaissance Technologies LLC grew its position in Xenetic Biosciences, Inc. (NASDAQ:XBIO – Free Report) by 516.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 178,509 shares of the company’s stock after buying an additional 149,559 shares during the quarter. Renaissance Technologies LLC owned 7.80% of Xenetic Biosciences worth $387,000 at the end of the most recent quarter. Institutional investors and hedge funds own 15.12% of the company’s stock.
Xenetic Biosciences Trading Up 3.3%
XBIO stock opened at $2.82 on Tuesday. The firm has a 50 day moving average of $3.01 and a 200-day moving average of $2.74. Xenetic Biosciences has a 12-month low of $1.90 and a 12-month high of $13.93. The company has a market cap of $6.46 million, a price-to-earnings ratio of -2.35 and a beta of 2.19.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Xenetic Biosciences currently has a consensus rating of “Sell”.
View Our Latest Research Report on XBIO
About Xenetic Biosciences
Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.
At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.
Featured Stories
- Five stocks we like better than Xenetic Biosciences
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
